Pasithea Therapeutics Corp Stock Performance
| KTTA Stock | USD 5.60 0.09 1.58% |
The company holds a Beta of 0.91, which implies possible diversification benefits within a given portfolio. Pasithea Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Pasithea Therapeutics is expected to follow. At this point, Pasithea Therapeutics has a negative expected return of -0.4%. Please make sure to check Pasithea Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Pasithea Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.0018 | Five Day Return 0.001786 | Year To Date Return (30.43) | Ten Year Return (92.13) | All Time Return (92.13) |
Last Split Factor 1:20 | Last Split Date 2024-01-02 |
1 | Acquisition by Steinman Lawrence of 100000 shares of Pasithea Therapeutics at 6.0 subject to Rule 16b-3 | 03/14/2024 |
2 | Pasithea Therapeutics Stock Price Down 2.1 percent - Defense World | 03/27/2024 |
3 | Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers | 04/24/2024 |
4 | Acquisition by Tiago Marques of 200000 shares of Pasithea Therapeutics at 1.44 subject to Rule 16b-3 | 05/02/2024 |
5 | Pasithea Therapeutics Stock Price Down 1.8 percent - Defense World | 06/04/2024 |
| Begin Period Cash Flow | 33.1 M |
Pasithea |
Pasithea Therapeutics Relative Risk vs. Return Landscape
If you would invest 750.00 in Pasithea Therapeutics Corp on March 10, 2024 and sell it today you would lose (190.00) from holding Pasithea Therapeutics Corp or give up 25.33% of portfolio value over 90 days. Pasithea Therapeutics Corp is currently does not generate positive expected returns and assumes 3.8004% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Pasithea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pasithea Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pasithea Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pasithea Therapeutics Corp, and traders can use it to determine the average amount a Pasithea Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1051
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KTTA |
Estimated Market Risk
| 3.8 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pasithea Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pasithea Therapeutics by adding Pasithea Therapeutics to a well-diversified portfolio.
Pasithea Therapeutics Fundamentals Growth
Pasithea Stock prices reflect investors' perceptions of the future prospects and financial health of Pasithea Therapeutics, and Pasithea Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pasithea Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | (9.32 M) | ||||
| Shares Outstanding | 1.04 M | ||||
| Price To Book | 0.33 X | ||||
| Price To Sales | 42.15 X | ||||
| Revenue | 486.56 K | ||||
| Gross Profit | (2.21 K) | ||||
| EBITDA | (15.33 M) | ||||
| Net Income | (15.51 M) | ||||
| Cash And Equivalents | 47.94 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 81.68 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 51.17 X | ||||
| Book Value Per Share | 22.46 X | ||||
| Cash Flow From Operations | (13.43 M) | ||||
| Earnings Per Share | (13.74) X | ||||
| Market Capitalization | 5.94 M | ||||
| Total Asset | 26.12 M | ||||
| Retained Earnings | (35.32 M) | ||||
| Working Capital | 14.06 M | ||||
About Pasithea Therapeutics Performance
To evaluate Pasithea Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Pasithea Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Pasithea Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Pasithea Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Pasithea's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (22.80) | (23.94) | |
| Return On Tangible Assets | (0.94) | (0.90) | |
| Return On Capital Employed | (0.68) | (0.71) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about Pasithea Therapeutics performance evaluation
Checking the ongoing alerts about Pasithea Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pasithea Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pasithea Therapeutics generated a negative expected return over the last 90 days | |
| Pasithea Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 486.56 K. Net Loss for the year was (15.51 M) with loss before overhead, payroll, taxes, and interest of (2.21 K). | |
| Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Latest headline from news.google.com: Pasithea Therapeutics Stock Price Down 1.8 percent - Defense World |
- Analyzing Pasithea Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pasithea Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pasithea Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pasithea Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pasithea Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pasithea Therapeutics' stock. These opinions can provide insight into Pasithea Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |